• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent


News you can use


All the latest conference updates; those that we are attending and the studies that we are presenting

Transpharmation Ltd are one of the partners to receive the prestigious Horizon 2020 Grant


We are delighted to announce that Transpharmation Ltd is to be one of the partners enlisted in the EU-funded first international project to study dystrophin in the brain in Duchenne and Becker Muscular Dystrophy (DMD and BMD).

Intellectual disability and neurobehavioural comorbidities affect at least 50% of the individuals with DMD, which, although a rare genetic disease, is the most common form of muscular dystrophy in childhood.

Being the part of the BIND project - an acronym for Brain Involvement in Dystrophinopathies - means that Transpharmation can be directly involved in deep phenotyping of multiple transgenic mice lines (DMD transgenic models) and postnatal restoration of one dystrophin isoform using genetic therapies. Moving towards the development of treatment for any type of illness is worthwhile, however, when it's for children it feels even more profound.



Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design